MedTrace Logo

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel in Gastric Cancer Patients With Peritoneal Metastasis

NCT04913662 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-06-04

No results posted yet for this study

Summary

This is a phase I trial investigating the safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel combined with intravenous FOLFOX therapy for gastric cancer patients with peritoneal metastasis.

Conditions

  • Stomach Neoplasm
  • Peritoneal Metastases

Interventions

PROCEDURE

Pressurized Intraperitoneal Aerosol Chemotherapy

Aerosolization of chemotherapic agent for intraperitoneal chemotherapy

Sponsors & Collaborators

  • Hospicare Co., Ltd.

    collaborator INDUSTRY

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2022-04-26
Completion
2022-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913662 on ClinicalTrials.gov